Goldman Sachs
PTCT icon

Goldman Sachs’s PTC Therapeutics PTCT Stock Holding History

Goldman Sachs’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.4M Sell
827,631
-195,460
-19% -$13.8M 0.01% 1484
2025
Q4 		$77.7M Buy
1,023,091
+146,682
+17% +$10.7M 0.01% 1166
2025
Q3 		$53.8M Buy
876,409
+100,656
+13% +$5.24M 0.01% 1360
2025
Q2 		$37.9M Buy
775,753
+173,088
+29% +$8.22M 0.01% 1545
2025
Q1 		$30.7M Sell
602,665
-161,960
-21% -$8.08M 0.01% 1634
2024
Q4 		$34.5M Sell
764,625
-57,816
-7% -$2.47M 0.01% 1605
2024
Q3 		$30.5M Buy
822,441
+31,277
+4% +$1.05M ﹤0.01% 1674
2024
Q2 		$24.2M Buy
791,164
+311,143
+65% +$10.1M ﹤0.01% 1729
2024
Q1 		$14M Sell
480,021
-46,473
-9% -$1.3M ﹤0.01% 2155
2023
Q4 		$14.5M Buy
526,494
+186,608
+55% +$4.27M ﹤0.01% 2196
2023
Q3 		$7.62M Sell
339,886
-86,346
-20% -$3.21M ﹤0.01% 2624
2023
Q2 		$17.3M Sell
426,232
-26,450
-6% -$1.29M ﹤0.01% 1967
2023
Q1 		$21.9M Sell
452,682
-80,352
-15% -$3.67M 0.01% 1744
2022
Q4 		$20.3M Buy
533,034
+27,556
+5% +$1.15M 0.01% 1942
2022
Q3 		$25.4M Buy
505,478
+9,298
+2% +$456K 0.01% 1660
2022
Q2 		$19.9M Buy
496,180
+267,773
+117% +$9.39M 0.01% 1900
2022
Q1 		$8.52M Sell
228,407
-298,926
-57% -$11.5M ﹤0.01% 2844
2021
Q4 		$21M Buy
527,333
+299,114
+131% +$11.4M ﹤0.01% 2072
2021
Q3 		$8.49M Sell
228,219
-41,095
-15% -$1.69M ﹤0.01% 2878
2021
Q2 		$11.4M Sell
269,314
-244,789
-48% -$10.5M ﹤0.01% 2569
2021
Q1 		$24.3M Sell
514,103
-192,787
-27% -$11.4M 0.01% 1776
2020
Q4 		$43.1M Buy
706,890
+321,859
+84% +$19M 0.01% 1238
2020
Q3 		$18M Sell
385,031
-475,814
-55% -$23.4M 0.01% 1818
2020
Q2 		$43.7M Buy
860,845
+259,100
+43% +$12.7M 0.01% 1056
2020
Q1 		$26.8M Buy
601,745
+105,510
+21% +$5.31M 0.01% 1300
2019
Q4 		$23.8M Buy
496,235
+81,650
+20% +$3.47M 0.01% 1723
2019
Q3 		$14M Sell
414,585
-20,507
-5% -$893K ﹤0.01% 2089
2019
Q2 		$19.6M Sell
435,092
-178,935
-29% -$7.07M 0.01% 1871
2019
Q1 		$23.1M Buy
614,027
+83,113
+16% +$2.79M 0.01% 1745
2018
Q4 		$18.2M Sell
530,914
-270,729
-34% -$9.73M 0.01% 1876
2018
Q3 		$37.7M Sell
801,643
-185,860
-19% -$7.69M 0.01% 1426
2018
Q2 		$33.3M Buy
987,503
+566,208
+134% +$17.7M 0.01% 1523
2018
Q1 		$11.4M Sell
421,295
-375,223
-47% -$9.51M ﹤0.01% 2230
2017
Q4 		$13.3M Buy
796,518
+514,068
+182% +$8.7M ﹤0.01% 2238
2017
Q3 		$5.65M Buy
282,450
+54,973
+24% +$1.08M ﹤0.01% 3033
2017
Q2 		$4.17M Sell
227,477
-71,358
-24% -$961K ﹤0.01% 3214
2017
Q1 		$2.94M Buy
298,835
+217,192
+266% +$2.63M ﹤0.01% 3383
2016
Q4 		$891K Sell
81,643
-67,956
-45% -$713K ﹤0.01% 4556
2016
Q3 		$2.1M Buy
149,599
+80,576
+117% +$655K ﹤0.01% 3795
2016
Q2 		$485K Buy
69,023
+56,265
+441% +$413K ﹤0.01% 4874
2016
Q1 		$82K Sell
12,758
-218,285
-94% -$3.79M ﹤0.01% 6173
2015
Q4 		$7.49M Buy
231,043
+160,230
+226% +$4.72M ﹤0.01% 2486
2015
Q3 		$1.89M Buy
70,813
+20,840
+42% +$891K ﹤0.01% 3856
2015
Q2 		$2.4M Buy
49,973
+16,097
+48% +$939K ﹤0.01% 3659
2015
Q1 		$2.06M Buy
33,876
+14,293
+73% +$872K ﹤0.01% 3752
2014
Q4 		$1.01M Sell
19,583
-12,874
-40% -$567K ﹤0.01% 4547
2014
Q3 		$1.43M Buy
+32,457
New +$1.02M ﹤0.01% 4250
2014
Q1 		– Sell
-17,407
Closed -$295K – 6889
2013
Q4 		$295K Sell
17,407
-9,869
-36% -$173K ﹤0.01% 5707
2013
Q3 		$585K Buy
+27,276
New +$474K ﹤0.01% 5044

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs's PTCT Position: Q1 2026 in Review

Goldman Sachs reduced its PTC Therapeutics (PTCT) stake by 19% in Q1 2026, selling an estimated $13.8M and leaving 827,631 shares worth $56.4M. The position accounts for 0.01% of the portfolio, ranked #1484.

Goldman Sachs first reported a position in PTCT in Q3 2013 and has held it in 49 quarters since. The position peaked at $77.7M in Q4 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Goldman Sachs held 827,631 shares of PTC Therapeutics worth $56.4M as of Q1 2026.
  • Goldman Sachs sold 195,460 PTC Therapeutics shares in Q1 2026, an estimated $13.8M.
  • PTC Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1484 holding.
  • Goldman Sachs first reported a position in PTC Therapeutics in Q3 2013 and has held it in 49 quarters since.
  • Goldman Sachs's PTC Therapeutics position peaked at $77.7M in Q4 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.